First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis
Durva-mono is a cost-effective treatment strategy for patients with R/M HNSCC, particularly in patients with high PD-L1 expression, compared with EXTREME or Durva-Treme. Cetuximab cost reduction may benefit the EXTREME regimen economically. Nevertheless, Durva-Treme provided fewer survival gains at substantial additional costs; therefore, it is unlikely to be a cost-effective option.
Authors
- Xueyan Liang (ORCID: https://orcid.org/0000-0002-4043-6066)
- Li‐Ju Huang (ORCID: https://orcid.org/0000-0002-3134-8590)
- Huijuan Li (ORCID: https://orcid.org/0000-0002-1070-3776)
- Xiaoyu Chen (ORCID: https://orcid.org/0000-0001-8860-747X)
- Yan Li (ORCID: https://orcid.org/0000-0003-1644-2308)
- Shiran Qin
Institutions
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1371/journal.pone.0324057
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00